Skip to content

Evaluating the effectiveness of a nerve block procedure for pain management in patients suffering from chronic pancreatitis

Randomized trial of EUS-guided celiac plexus block vs sham for palliation of pain in chronic pancreatitis (EPOCH trial) - EPOCH

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/06/111549
Enrollment
94
Registered
2026-06-01
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K861- Other chronic pancreatitis

Interventions

Intervention1: Endoscopic ultrasound-guided celiac plexus block: Under EUS-guidance, celiac plexus block will be performed with injection of bupivacaine and triamcinolone into the area of celiac plexu

Sponsors

Orlando Health, Inc.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age greater than or equal to 18 years. Abdominal pain of at least 3 months duration and a VAS score greater than or equal to 3, with or without the use of narcotic analgesics. Diagnosis of Chronic Pancreatitis on EUS examination, with greater than or equal to 5 features on EUS. No other cause of abdominal pain.

Exclusion criteria

Exclusion criteria: Age less than 18 years. History of prior EUS-CPB. ERCP for management of chronic pancreatitis within the last 1 year. Use of anticoagulants that cannot be discontinued for the procedure. Clinically significant allergy to bupivacaine or triamcinolone. Unable to obtain consent for the procedure from either the patient or LAR. Intrauterine pregnancy.

Design outcomes

Primary

MeasureTime frame
Rate of adequate pain reliefTimepoint: 1 month

Secondary

MeasureTime frame
Technical successTimepoint: Immediately after procedure;Pain scores measured using Visual Analog Scale.Timepoint: 3 months;Pain scores measured using the Comprehensive Pain Assessment Tool-Short Form.Timepoint: 3 months;Quality of life assessmentTimepoint: 3 months;Opioid analgesic useTimepoint: 3 months;Procedure-related adverse eventsTimepoint: 3 months;Disease-related adverse eventsTimepoint: 3 months;Hospital admissions for management of chronic pancreatitis.Timepoint: 3 months;Length of hospitalization in any patient hospitalizedTimepoint: 3 months;Rate of cross-over to EUS-CPB in patients initially assigned to the sham group.Timepoint: 3 months;Rate of need for any additional endoscopic, surgical or radiological intervention for chronic pancreatitis.Timepoint: 3 months

Countries

India

Contacts

Public ContactDr Shubham Mehta

Medanta The Medicity

hbp310894@gmail.com07984434399

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026